HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells.

Abstract
Enolase-alpha (ENO-1) is a key glycolytic enzyme that has been used as a diagnostic marker to identify human lung cancers. To investigate the role of ENO-1 in breast cancer diagnosis and therapy, the mRNA levels of ENO-1 in 244 tumor and normal paired tissue samples and 20 laser capture-microdissected cell clusters were examined by quantitative real-time PCR analysis. Increased ENO-1 mRNA expression was preferentially detected in estrogen receptor-positive (ER+) tumors (tumor/normal ratio >90-fold) when compared to ER-negative (tumor/normal ratio >20-fold) tumor tissues. The data presented here demonstrate that those patients whose tumors highly expressed ENO-1 had a poor prognosis with greater tumor size (>2 cm, *P = .017), poor nodal status (N > 3, *P = .018), and a shorter disease-free interval (<==1 year, *P < .009). We also found that higher-expressing ENO-1 tumors confer longer distance relapse (tumor/normal ratio = 82.8-92.4-fold) when compared to locoregional relapse (tumor/normal ratio = 43.4-fold) in postsurgical 4-hydroxy-tamoxifen (4-OHT)-treated ER+ patients (*P = .014). These data imply that changes in tumor ENO-1 levels are related to clinical 4-OHT therapeutic outcome. In vitro studies demonstrated that decreasing ENO-1 expression using small interfering RNA (siRNA) significantly augmented 4-OHT (100 nM)-induced cytotoxicity in tamoxifen-resistant (Tam-R) breast cancer cells. These results suggest that downregulation of ENO-1 could be utilized as a novel pharmacological approach for overcoming 4-OHT resistance in breast cancer therapy.
AuthorsShih-Hsin Tu, Chih-Chiang Chang, Ching-Shyang Chen, Ka-Wai Tam, Ying-Jan Wang, Chia-Hwa Lee, Hsiao-Wei Lin, Tzu-Chun Cheng, Ching-Shui Huang, Jan-Show Chu, Neng-Yao Shih, Li-Ching Chen, Sy-Jye Leu, Yuan-Soon Ho, Chih-Hsiung Wu
JournalBreast cancer research and treatment (Breast Cancer Res Treat) Vol. 121 Issue 3 Pg. 539-53 (Jun 2010) ISSN: 1573-7217 [Electronic] Netherlands
PMID19655245 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents, Hormonal
  • Biomarkers, Tumor
  • DNA-Binding Proteins
  • Estrogen Receptor alpha
  • NF-kappa B
  • RNA, Messenger
  • RNA, Small Interfering
  • Tumor Suppressor Proteins
  • Tamoxifen
  • ENO1 protein, human
  • Phosphopyruvate Hydratase
Topics
  • Adult
  • Aged
  • Antineoplastic Agents, Hormonal (pharmacology)
  • Biomarkers, Tumor (antagonists & inhibitors, metabolism)
  • Breast Neoplasms (drug therapy, pathology)
  • Case-Control Studies
  • Cells, Cultured
  • DNA-Binding Proteins (antagonists & inhibitors, metabolism)
  • Drug Resistance, Neoplasm
  • Drug Screening Assays, Antitumor
  • Estrogen Receptor alpha (metabolism)
  • Female
  • Humans
  • Middle Aged
  • NF-kappa B (metabolism)
  • Phosphopyruvate Hydratase (antagonists & inhibitors, metabolism)
  • Prognosis
  • RNA, Messenger (analysis)
  • RNA, Small Interfering
  • Survival Analysis
  • Tamoxifen (pharmacology)
  • Tumor Suppressor Proteins (antagonists & inhibitors, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: